Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis

Rodrigues, Patrícia; Bochi, Guilherme Vargas; Trevisan, Gabriela

doi:10.1007/s12035-021-02493-9

Cited by 14 publications

(10 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Obradovic et al [ 20 ], the decrease in the concentration of AOPP was shown to be a good prognostic parameter for clinical outcomes in MS patients, including recovery after treatment of relapse [ 20 ]. A similar conclusion was made in the meta-analysis conducted by Rodrigues et al [ 35 ], who claimed that AOPP may represent a new target for drug development in MS treatment and a possible biomarker to monitor the severity of the disease.…”

Section: Discussionsupporting

confidence: 74%

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies

Bizoń

Chojdak-Łukasiewicz²,

Kołtuniuk³

et al. 2022

Antioxidants

View full text Add to dashboard Cite

The aim of this study was to evaluate oxidative stress parameters, specifically the concentration of advanced oxidation protein products (AOPP) and ferric-reducing antioxidant power (FRAP), in the serum of patients with relapsing-remitting multiple sclerosis (RRMS). We also analyzed the relationships between each parameter and selected clinical/laboratory multiple-sclerosis-related parameters. The study group comprised 204 patients with RRMS and 29 healthy, age-matched controls. The concentration of AOPP was significantly higher in the RRMS patients than in controls. ROC analysis showed the ability of AOPP to distinguish between the patients with RRMS and controls (the value of AUC was 94.8%, with a sensitivity of 89.69% and specificity of 89.3%). AOPP and FRAP were significantly higher in male than in female RRMS patients. Correlations were found between AOPP and the laboratory markers of inflammation. AOPP differed in the subgroups of patients treated with particular medications. Our findings indicate an increase in the markers of oxidative stress in the serum of RRMS patients, possibly linked with chronic inflammation. Gender and type of treatment affected the markers of oxidative stress.

show abstract

Section: Discussionsupporting

confidence: 74%

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies

Bizoń

Chojdak-Łukasiewicz²,

Kołtuniuk³

et al. 2022

Antioxidants

View full text Add to dashboard Cite

show abstract

“…Pooling the data was performed with the random-effects model using weighted averages relative to the sample size of the single studies ( DerSimonian and Laird, 1986 ). We considered the risk of bias results, so when a study presented more than two standard deviations (SD) than the total percentage of high bias (41%), we excluded it from the analysis ( Rodrigues et al, 2021 ). The meta-analysis was performed using the total number of MS patients and the percentage of patients with anxiety or depression.…”

Section: Methodsmentioning

confidence: 99%

Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis

Peres

Rodrigues

Viero

et al. 2022

Brain, Behavior, & Immunity - Health

Self Cite

View full text Add to dashboard Cite

“…as an end-point for evaluating the therapy response for natalizumab, interferon-beta, and mitoxantrone previously (Rodrigues et al, 2021;Tasset et al, 2013). However, studies on fingolimod are rare and TDH and IMA have not been specifically considered before.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, the molecular mechanisms underlying inter‐individual differences in MS therapy response have not been understood completely. Oxidative and nitrosative stress have been addressed as an end‐point for evaluating the therapy response for natalizumab, interferon‐beta, and mitoxantrone previously (Rodrigues et al, 2021; Tasset et al, 2013). However, studies on fingolimod are rare and TDH and IMA have not been specifically considered before.…”

Section: Discussionmentioning

confidence: 99%

Neurocognitive impairment in multiple sclerosis and its association with thiol‐disulfide homeostasis and ischemia‐modified albumin

Demirdöğen

Kilic

Mungan

et al. 2023

J of Neuroscience Research

View full text Add to dashboard Cite

This study aimed to assess the possible association between cognitive impairment and two important biochemical biomarkers of oxidative stress, thiol‐disulfide homeostasis (TDH), and ischemia‐modified albumin (IMA) in patients with multiple sclerosis (MS). This study included 85 patients with MS (38 treatment‐naïve relapsing–remitting MS (RRMS), 31 RRMS on fingolimod therapy, and 16 secondary progressive MS (SPMS)) and 33 healthy controls. Cognitive evaluation was carried out by applying the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) test battery and the scores were adjusted for age and years of education. Plasma TDH was assessed using an automated method and plasma IMA levels were determined using the cobalt‐albumin binding assay. Plasma native thiol and total thiol levels were significantly decreased in patients with SPMS when compared with the naïve patients and healthy controls. Cognitive impairment was detected in 47.4% of naïve patients, 64.5% of patients on fingolimod therapy, and 80% of patients with SPMS. Naïve patients or patients on fingolimod therapy who were cognitively impaired had significantly decreased levels of native thiol and total thiol compared to the cognitively normal patients. Logistic regression analysis revealed total thiol and native thiol to be significantly associated with cognitive impairment in naïve patients and patients on fingolimod therapy. Significant correlations were determined between BICAMS scores, TDH, IMA, clinical indices of disease severity (EDSS and MSSS), and magnetic resonance imaging parameters. This study has shown for the first time that plasma TDH parameters are associated with cognitive impairment in MS.

show abstract

Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis

Cited by 14 publications

References 58 publications

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies

Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis

Neurocognitive impairment in multiple sclerosis and its association with thiol‐disulfide homeostasis and ischemia‐modified albumin

Contact Info

Product

Resources

About